Date : 11th of November 2014 from 09:00 to 13:45
Location: BioArk, Monthey

“Therapeutic Recombinant Proteins  : Next Generation”

Not only recombinant proteins are now considered as excellent therapeutic approaches, but several blockbusters on the market belong to this class of molecules. Of the ten best-selling drugs in 2012, six of them were monoclonal antibody drugs, each with annual sales value exceeding US$5 billion. Nevertheless, the field in terms of innovation is still very open and suggests business opportunities that are currently in development for some of them, or even, entering the market for the others.

On the 11^th of November, the speakers of the “Therapeutic Recombinant Proteins - Next Generation” event will cover the wide range of business and innovation opportunities.

• How innovation can support optimization of manufacturing costs?
• Are disposable technologies viable manufacturing solutions?
• What about biosimilar’s development?
• Antibody-drug conjugates - trend or business reality?
• Formulation and analytics - where are the key issues in terms of biopharmaceutical development?

Please find the program here below. The event will be followed by a lunch hosted by BioArk.

Admission is free but registration required until the 7th of November 2014.

Best regards,

Massimo Nobile
BioArk Site manager

Program